Middlemore Hospital
Auckland, Middlemore, New Zealand
3 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled443 locationsNCT06632457
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled452 locationsNCT06531824
Recruiting
Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled524 locationsNCT06632444
Recruiting
Phase 3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Ischemic Stroke; Ischemic Attack, Transient
Janssen Research & Development, LLC15,000 enrolled880 locationsNCT05702034
Recruiting
Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Community-acquired Pneumonia
Biotest590 enrolled147 locationsNCT05722938
Recruiting
Phase 3
Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial
Breast CancerMastectomyBreast Cancer Female+1 more
Monash University4,300 enrolled47 locationsNCT05072314
Recruiting
Not Applicable
Platform of Randomized Adaptive Clinical Trials in Critical Illness
Respiratory InsufficiencyMechanical Ventilation Pressure HighExtracorporeal Membrane Oxygenation Complication
University Health Network, Toronto6,250 enrolled86 locationsNCT05440851
Recruiting
Not Applicable
A Platform Trial for Gram Negative Bloodstream Infections
Gram-negative Bacteremia
Sunnybrook Health Sciences Centre2,500 enrolled39 locationsNCT06537609
Recruiting
Phase 2
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Myelodysplastic SyndromesCytopenia
Takeda160 enrolled47 locationsNCT04419649
Recruiting
Phase 3
Fibrinogen Early In Severe Trauma StudY II
coagulopathyTraumaHaemorrhagic Shock
Australian and New Zealand Intensive Care Research Centre900 enrolled24 locationsNCT05449834
Recruiting
Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
Neonatal EncephalopathyNeonatal SeizureSeizure Newborn+1 more
University of California, San Diego133 enrolled5 locationsNCT05610085
Recruiting
Phase 4
Staphylococcus Aureus Network Adaptive Platform Trial
Staphylococcus Aureus Bacteremia
University of Melbourne8,000 enrolled151 locationsNCT05137119
Recruiting
Phase 3
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
Multiple traumaTraumatic Brain InjuryWounds and Injuries+5 more
Australian and New Zealand Intensive Care Research Centre2,500 enrolled41 locationsNCT04588311
Recruiting
Not Applicable
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
Kidney Failure, ChronicHyperphosphatemia
The University of Queensland3,600 enrolled115 locationsNCT03573089
Recruiting
Phase 3
Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction
Pregnancy PretermFetal Growth RetardationStillbirth and Fetal Death
Monash University336 enrolled12 locationsNCT05651347
Recruiting
Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Community-acquired Pneumonia, Influenza, COVID-19
UMC Utrecht20,000 enrolled408 locationsNCT02735707
Recruiting
Not Applicable
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
Sudden Cardiac Death
Western Sydney Local Health District1,058 enrolled52 locationsNCT03588286